TW202231662A - 抗肌抑素抗體、含變異fc區之多肽及使用方法 - Google Patents

抗肌抑素抗體、含變異fc區之多肽及使用方法 Download PDF

Info

Publication number
TW202231662A
TW202231662A TW110149330A TW110149330A TW202231662A TW 202231662 A TW202231662 A TW 202231662A TW 110149330 A TW110149330 A TW 110149330A TW 110149330 A TW110149330 A TW 110149330A TW 202231662 A TW202231662 A TW 202231662A
Authority
TW
Taiwan
Prior art keywords
amino acid
antibody
seq
region
hvr
Prior art date
Application number
TW110149330A
Other languages
English (en)
Chinese (zh)
Inventor
倉持太一
井川智之
堅田仁
堀裕次
Original Assignee
日商中外製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商中外製藥股份有限公司 filed Critical 日商中外製藥股份有限公司
Publication of TW202231662A publication Critical patent/TW202231662A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW110149330A 2015-12-18 2016-12-16 抗肌抑素抗體、含變異fc區之多肽及使用方法 TW202231662A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015-247070 2015-12-18
JP2015247070 2015-12-18

Publications (1)

Publication Number Publication Date
TW202231662A true TW202231662A (zh) 2022-08-16

Family

ID=59011957

Family Applications (3)

Application Number Title Priority Date Filing Date
TW105141729A TWI605057B (zh) 2015-12-18 2016-12-16 抗肌抑素抗體、含變異ｆｃ區之多肽及使用方法
TW110149330A TW202231662A (zh) 2015-12-18 2016-12-16 抗肌抑素抗體、含變異fc區之多肽及使用方法
TW106129765A TWI749057B (zh) 2015-12-18 2016-12-16 抗肌抑素抗體、含變異ｆｃ區之多肽及使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TW105141729A TWI605057B (zh) 2015-12-18 2016-12-16 抗肌抑素抗體、含變異ｆｃ區之多肽及使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW106129765A TWI749057B (zh) 2015-12-18 2016-12-16 抗肌抑素抗體、含變異ｆｃ區之多肽及使用方法

Country Status (16)

Country Link
EP (1) EP3390443A4 (de)
JP (4) JP6142069B1 (de)
KR (4) KR102501335B1 (de)
CN (2) CN115028721A (de)
AR (1) AR107078A1 (de)
AU (1) AU2016372934B2 (de)
BR (1) BR112018011073A2 (de)
CA (1) CA3002422C (de)
EA (1) EA201891420A1 (de)
HK (1) HK1254755A1 (de)
MX (1) MX2018007145A (de)
MY (1) MY189425A (de)
PH (1) PH12018501280A1 (de)
SG (2) SG10201707267RA (de)
TW (3) TWI605057B (de)
WO (1) WO2017104783A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4342995A3 (de) 2006-03-31 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Verfahren zur kontrolle der blut-pharmazeutizität von antikörpern
WO2009041643A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha Cdrのアミノ酸置換により抗体の等電点を改変する方法
JP4954326B2 (ja) 2008-04-11 2012-06-13 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
EP4231014A3 (de) 2010-11-30 2024-03-20 Chugai Seiyaku Kabushiki Kaisha Antigenbindende moleküle zur wiederholten bindung an mehrere antigenmoleküle
WO2013180200A1 (ja) 2012-05-30 2013-12-05 中外製薬株式会社 標的組織特異的抗原結合分子
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
NZ705370A (en) 2012-08-24 2018-06-29 Chugai Pharmaceutical Co Ltd Fcγriib-specific fc region variant
KR102318483B1 (ko) 2013-04-02 2021-10-27 추가이 세이야쿠 가부시키가이샤 Ｆｃ영역 개변체
TW202043467A (zh) 2013-12-04 2020-12-01 日商中外製藥股份有限公司 因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫
MY181199A (en) 2014-12-19 2020-12-21 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
CN107108729A (zh) 2015-02-05 2017-08-29 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用
JP6142069B1 (ja) * 2015-12-18 2017-06-07 中外製薬株式会社 抗ミオスタチン抗体、変異Ｆｃ領域を含むポリペプチド、および使用方法
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
AU2017285764B2 (en) * 2016-06-17 2024-05-02 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
KR20230079499A (ko) 2016-08-05 2023-06-07 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
CA3052837A1 (en) 2017-02-28 2018-09-07 Seattle Genetics, Inc. Cysteine mutated antibodies for conjugation
BR112021002037A2 (pt) 2018-08-10 2021-05-04 Chugai Seiyaku Kabushiki Kaisha molécula de ligação de antígeno anti-cd137 e uso da mesma
JPWO2020209318A1 (de) * 2019-04-10 2020-10-15
MX2022002855A (es) * 2019-09-13 2022-06-02 Admare Therapeutics Soc Anticuerpos antiantígenos de virus oncolíticos y métodos de uso de los mismos.
RU2750267C1 (ru) * 2020-02-07 2021-06-25 Общество с ограниченной ответственностью «НАУЧНО-ПРОИЗВОДСТВЕННОЕ ОБЪЕДИНЕНИЕ ИН-ВЕТ» Рекомбинантный ростовой дифференцировочный фактор роста 11 (GDF11), способ его получения, инъекционный препарат для повышения мышечной массы млекопитающих животных и птицы, а также способ использования препарата
TW202144395A (zh) 2020-02-12 2021-12-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
WO2023057404A1 (en) 2021-10-06 2023-04-13 F. Hoffmann-La Roche Ag Novel combined administration
TW202346345A (zh) 2022-04-01 2023-12-01 瑞士商赫孚孟拉羅股份公司 面肩胛肱肌失養症（ｆｓｈｄ）之新治療
WO2023213779A1 (en) 2022-05-02 2023-11-09 Novo Nordisk A/S Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutaneous administration
US20240173325A1 (en) 2022-10-14 2024-05-30 Genentech, Inc. Methods for treating spinal muscular atrophy
CN116990528B (zh) * 2023-09-27 2024-02-06 成都华西海圻医药科技有限公司 一种基于Gyrolab平台快速测定抗CD40单抗的分析方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
AR047392A1 (es) * 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
EP1797127B1 (de) * 2004-09-24 2017-06-14 Amgen Inc. Modifizierte fc-moleküle
US8008453B2 (en) * 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
JP5058261B2 (ja) * 2006-09-05 2012-10-24 イーライ リリー アンド カンパニー 抗ミオスタチン抗体
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
JP4954326B2 (ja) * 2008-04-11 2012-06-13 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
UY32341A (es) * 2008-12-19 2010-07-30 Glaxo Group Ltd Proteínas de unión antígeno novedosas
SA111320266B1 (ar) * 2010-03-11 2015-06-21 رينات نيوروساينس كوربوريشن أجسام مضادة مع ارتباط مولد مضاد يعتمد على الأس الهيدروجيني
UY33421A (es) * 2010-06-03 2011-12-30 Glaxo Wellcome House Proteinas de union al antígeno humanizados
KR102228296B1 (ko) * 2012-03-16 2021-03-17 리제너론 파마슈티칼스 인코포레이티드 히스티딘 공학처리된 경쇄 항체 및 그것을 생성하기 위한 유전자 변형된 비-사람 동물
TWI619729B (zh) * 2012-04-02 2018-04-01 再生元醫藥公司 抗－ｈｌａ－ｂ*２７抗體及其用途
CA2881679C (en) * 2012-08-13 2021-01-26 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 antibodies with ph-dependent binding characteristics
NZ705370A (en) * 2012-08-24 2018-06-29 Chugai Pharmaceutical Co Ltd Fcγriib-specific fc region variant
AU2014262843B2 (en) * 2013-05-06 2017-06-22 Scholar Rock, Inc. Compositions and methods for growth factor modulation
AU2014307589A1 (en) * 2013-08-14 2016-02-11 Novartis Ag Methods of treating sporadic inclusion body myositis
WO2016073879A2 (en) * 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related antibodies and uses thereof
CA3005158A1 (en) * 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
MY181199A (en) * 2014-12-19 2020-12-21 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
JP6142069B1 (ja) 2015-12-18 2017-06-07 中外製薬株式会社 抗ミオスタチン抗体、変異Ｆｃ領域を含むポリペプチド、および使用方法

Also Published As

Publication number Publication date
JP2024023427A (ja) 2024-02-21
TWI749057B (zh) 2021-12-11
RU2018125431A (ru) 2020-01-20
KR20230027321A (ko) 2023-02-27
PH12018501280A1 (en) 2019-01-28
EP3390443A4 (de) 2019-11-13
TW201726718A (zh) 2017-08-01
KR20180085711A (ko) 2018-07-27
JP6142069B1 (ja) 2017-06-07
RU2018125431A3 (de) 2020-07-06
HK1254755A1 (zh) 2019-07-26
CN108473562B (zh) 2022-06-17
CA3002422C (en) 2024-04-16
KR20170085028A (ko) 2017-07-21
AU2016372934A1 (en) 2018-05-10
AU2016372934B2 (en) 2023-10-05
MY189425A (en) 2022-02-10
EP3390443A1 (de) 2018-10-24
JP2022097485A (ja) 2022-06-30
WO2017104783A1 (en) 2017-06-22
AR107078A1 (es) 2018-03-21
JP2017148069A (ja) 2017-08-31
MX2018007145A (es) 2018-08-15
CN108473562A (zh) 2018-08-31
JP2017112997A (ja) 2017-06-29
JP7053164B2 (ja) 2022-04-12
SG10201707267RA (en) 2017-10-30
CN115028721A (zh) 2022-09-09
CA3002422A1 (en) 2017-06-22
KR102501335B1 (ko) 2023-02-17
BR112018011073A2 (pt) 2018-11-21
KR20240058997A (ko) 2024-05-03
TWI605057B (zh) 2017-11-11
KR101820637B1 (ko) 2018-01-19
EA201891420A1 (ru) 2019-02-28
SG11201610812WA (en) 2017-07-28
TW201808992A (zh) 2018-03-16

Similar Documents

Publication Publication Date Title
US11454633B2 (en) Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
JP7342177B2 (ja) 抗ミオスタチン抗体および使用方法
TWI749057B (zh) 抗肌抑素抗體、含變異ｆｃ區之多肽及使用方法
EA041641B1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения